Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Deutsche Bank lifts Jupiter price target on CCLA acquisition

(Sharecast News) - Deutsche Bank lifted its price target on Jupiter Fund Management on Friday to 110p from 90p after it agreed to buy CCLA - the UK's largest asset manager focused on serving non-profit organisations - for £100m. The bank said it has updated its forecast and price target to reflect the "financially and strategically sensible deal".

"Assuming the material cost synergies targeted can be realised, and without significant revenue dissynergy (which looks plausible in this case, given limited client/product overlap), we consider the acquisition inexpensive and a sensible use of part of the current substantial surplus capital," DB said.

"In addition to the financial attractions, we believe the deal will improve diversification (and therefore resilience) of the group across both client (notably adding non-profit and local authority clients) and product (notably multi-asset, money market and property), and increase scale."

In turn, this should help to underpin a more stable group operating profit trajectory and consequently an improved/more resilient ordinary dividend outlook, the bank added.

DB rates the shares at 'hold'.

At 0935 BST, Jupiter shares were up 1.5% at 121.80p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.